Save time and money with MTBeurope (infliximab), Humira (adalimumab) and Rituxan (rituximab). The growth was further fuelled by the launch of safer and more efficacious biologics. During 2010-2018, the rheumatoid arthritis therapeutics market is expected to see moderate growth due to ... |
